Akathisia is a movement disorder defined by an intense inner restlessness and a near-irresistible urge to move, most often felt in the legs. It is primarily caused by medications that block dopamine receptors in the brain, and it affects roughly 14% to 35% of people taking antipsychotic drugs. The experience is often described as deeply uncomfortable, sometimes more distressing than the condition being treated.
How Akathisia Feels
Akathisia has two distinct layers: what you feel on the inside and what others can see on the outside. The inner experience is a sensation of unease or agitation, usually centered in the lower body. People describe it as an overwhelming compulsion to move, not because they choose to, but because staying still feels unbearable.
The outward signs follow from that inner drive. Someone with akathisia may pace back and forth, rock while seated, shift their weight from foot to foot, or repeatedly cross and uncross their legs. These movements aren’t random tics. They are deliberate, voluntary responses to an internal sensation that won’t quiet down. The key distinction is that the person is fully aware of both the feeling and the movements, and the movement provides only brief, partial relief.
Why It Happens
The most common trigger is medication. Antipsychotic drugs are the leading cause, but anti-nausea medications and some antidepressants (particularly SSRIs) can also produce it. The underlying mechanism involves dopamine, a brain chemical that plays a central role in movement control. These medications work by blocking dopamine receptors. In some parts of the brain, that blockade produces a therapeutic effect. But in the movement-control circuits of the basal ganglia, it disrupts the normal balance between dopamine and another chemical messenger, acetylcholine, and that disruption can trigger the restless, driven-to-move sensation of akathisia.
Older antipsychotics carry a substantially higher risk than newer ones. A 2019 meta-analysis comparing 32 antipsychotics found that certain older drugs increased the risk of akathisia by up to 24-fold compared to placebo, while some newer agents increased it by about twofold. Iron levels also appear to play a role: lower iron stores in the body have been linked to a higher likelihood of developing akathisia, and in some cases, intravenous iron supplementation has reduced symptoms.
How It Differs From Anxiety and Other Conditions
Akathisia is frequently misidentified as anxiety, and the two can look similar on the surface. Both involve restlessness and a feeling of being unable to settle. The critical difference is that akathisia is a movement disorder, not a mood disorder. It does not come with the fear, worry, or dread that define anxiety. The distress of akathisia is physical: a body that won’t let you be still. If you have akathisia and a clinician mistakes it for worsening anxiety, the response might be to increase the very medication causing the problem.
It also looks different from tardive dyskinesia, another movement side effect of the same class of drugs. Tardive dyskinesia involves involuntary, repetitive movements, often of the face, tongue, and jaw, like lip smacking or grimacing. Those movements happen without the person choosing them and sometimes without the person even noticing. Akathisia movements, by contrast, are voluntary. You pace because you can’t stand the feeling of not pacing. Six features help clinicians tell the two apart: the nature of the subjective distress, whether movements are voluntary or involuntary, when symptoms began, where in the body they show up, whether other movement side effects are present, and how the symptoms respond to medication changes.
Types and Timing
Not all akathisia arrives on the same schedule. Acute akathisia is the most common form and typically develops within days to weeks of starting a new medication or increasing a dose. This is the form most people experience, and it generally improves when the triggering medication is adjusted.
Tardive akathisia appears after months or years of treatment with the same drug. It is harder to treat because it may persist even after the medication is stopped. Withdrawal akathisia is a third pattern, emerging when a medication is reduced or discontinued rather than started. Recognizing which type you are dealing with matters because the management strategy differs for each.
How It Is Assessed
Clinicians evaluate akathisia using the Barnes Akathisia Rating Scale, a four-item tool. A clinician first observes the patient briefly and scores the visible restlessness on a scale of 0 to 3. Then the patient reports how aware they are of the restlessness (0 to 3) and how distressed it makes them feel (0 to 3). Those three scores feed into a global assessment that rates the overall severity from 0 (absent) through 5 (severe). This scoring system matters because akathisia can exist almost entirely as an inner experience. Someone might score low on observable movement but high on subjective distress, and both dimensions need attention.
Treatment and Management
The most straightforward step is adjusting the medication responsible. Lowering the dose or switching to a drug with a lower risk profile resolves symptoms for many people. When that isn’t possible, because the medication is essential for managing a serious condition, additional treatments can help manage the restlessness.
A beta-blocker called propranolol is the most studied add-on treatment. Even at low doses (starting around 10 mg twice daily), it has shown effectiveness, and one controlled study found it more helpful than a common sedative for this specific condition. Other options include certain medications that restore the dopamine-acetylcholine balance, as well as sedatives from the benzodiazepine class. None of these is considered a definitive cure. Treatment typically involves trying one approach, assessing the response, and adjusting from there.
For people with low iron levels, correcting that deficiency may provide additional benefit, given the link between iron status and akathisia risk.
Emotional Impact and Risks
Akathisia is not just physically uncomfortable. It can be profoundly distressing. Some studies have found that people with akathisia score higher on measures of depersonalization, agitation, and depressed mood. A correlation between akathisia and suicidal thoughts has been explored in research, but the evidence is mixed. Some studies found a weak link between akathisia and suicidal behavior, while others found no significant connection. A systematic review concluded that, based on available evidence, akathisia cannot be reliably linked to suicidal behavior in patients on antipsychotic medication.
What is clear is that unrecognized akathisia causes real suffering. People who aren’t told that their medication could cause this reaction may believe something is deeply wrong with them, or that their underlying condition is getting worse. That misunderstanding can lead to dose increases that make the problem worse. The single most important thing about akathisia is recognizing it for what it is: a medication side effect, not a worsening of the condition being treated, and one that can almost always be improved once it is correctly identified.